57874 20200221144342.0 doi 10.1136/lupus-2016-000153 sideral 96100 ART-2016-96100 eng Ruiz-Irastorza, G. First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort 2016 Access copy available to the general public Unrestricted Aim: To study the influence of prednisone dose during the first month after systemic lupus erythematosus (SLE) diagnosis (prednisone-1) on glucocorticoid burden during the subsequent 11 months (prednisone-2–12). Methods: 223 patients from the Registro Español de Lupus Eritematoso Sistémico inception cohort were studied. The cumulative dose of prednisone-1 and prednisone-2–12 were calculated and recoded into a four-level categorical variable: no prednisone, low dose (up to 7.5 mg/day), medium dose (up to 30 mg/day) and high dose (over 30 mg/day). The association between the cumulative prednisone-1 and prednisone-2–12 doses was tested. We analysed whether the four-level prednisone-1 categorical variable was an independent predictor of an average dose >7.5 mg/day of prednisone-2–12. Adjusting variables included age, immunosuppressives, antimalarials, methyl-prednisolone pulses, lupus nephritis and baseline SLE Disease Activity Index (SLEDAI). Results: Within the first month, 113 patients (51%) did not receive any prednisone, 24 patients (11%) received average low doses, 46 patients (21%) received medium doses and 40 patients (18%) received high doses. There was a strong association between prednisone-1 and prednisone-2–12 dose categories (p<0.001). The cumulative prednisone-1 dose was directly associated with the cumulative prednisone-2–12 dose (p<0.001). Compared with patients on no prednisone, patients taking medium (adjusted OR 5.27, 95% CI 2.18 to 12.73) or high-dose prednisone-1 (adjusted OR 10.5, 95% CI 3.8 to 29.17) were more likely to receive prednisone-2–12 doses of >7.5 mg/day, while patients receiving low-dose prednisone-1 were not (adjusted OR 1.4, 95% CI 0. 0.38 to 5.2). If the analysis was restricted to the 158 patients with a baseline SLEDAI of =6, the model did not change. Conclusion: The dose of prednisone during the first month after the diagnosis of SLE is an independent predictor of prednisone burden during the following 11 months. info:eu-repo/semantics/openAccess by-nc http://creativecommons.org/licenses/by-nc/3.0/es/ 1.248 2016 Medicine (miscellaneous) 2016 Q1 Immunology 2016 Q2 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Garcia, M. Espinosa, G. Caminal, L. Mitjavila, F. González-León, R. Sopenã, B. Canora, J. Villalba, M.V. Rodríguez-Carballeira, M. López-Dupla, J.M. Callejas, J.L. Castro, A. Tolosa, C. Sánchez-Garciá, M.E. (orcid)0000-0001-7563-7880 Pérez-Conesa, M. Universidad de Zaragoza Navarrete-Navarrete, N. Rodríguez, A.P. Herranz, M.T. Pallarés, L. 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 3, 1 (2016), e000153 [6 pp] Lupus sci. med. Lupus Science and Medicine 2053-8790 528523 http://zaguan.unizar.es/record/57874/files/texto_completo.pdf Versión publicada 39683 http://zaguan.unizar.es/record/57874/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:57874 articulos driver 2020-02-21-13:51:04 ARTICLE